Summary & Overview
HCPCS Level II Q5154: Omalizumab-igec (Omlyclo) Injection, 5 mg
HCPCS Level II code Q5154 denotes a 5 mg unit of omalizumab-igec (Omlyclo), a biosimilar formulation of omalizumab used for subcutaneous or injectable administration. Nationally, accurate coding for biosimilar biologics affects payment, prior authorization pathways, and product selection in allergy and immunology, pulmonology, and outpatient infusion settings. This code matters as biosimilar adoption expands and payers refine coverage and reimbursement policies for biologics.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what this code represents, typical sites of service, and the clinical context for omalizumab biosimilar use. The publication also outlines what to expect in payer coverage considerations, common modifiers in use, and related service-line implications where data are available.
The report provides benchmarks and policy context relevant to coding, billing, and administration of biosimilar injectable biologics, plus practical notes on documentation and claim reporting. Data not available in the input are reported as unavailable where applicable.
Billing Code Overview
HCPCS Level II code Q5154 describes an injection of omalizumab-igec (Omlyclo), biosimilar, 5 mg. The service is a drug administration consisting of a specified small-dose vial or unit of the biosimilar monoclonal antibody product.
Service Type: Drug administration / injectable biologic product
Typical Site of Service: Outpatient clinic, physician office, or infusion/infusion-capable outpatient setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, or another IgE-mediated condition who requires subcutaneous biologic therapy. The patient presents to an ambulatory infusion or allergy clinic for administration of Q5154 (injection, omalizumab-igec (Omlyclo), biosimilar, 5 mg). The clinical workflow begins with verification of the medication order, review of prior authorization and payor coverage, assessment of recent weight and baseline IgE as required for dosing, allergy and anaphylaxis history review, and vital sign measurement. The nurse prepares the dose per manufacturer guidance, confirms patient identity, documents lot number and expiration, and administers the injection subcutaneously. The patient is observed for an appropriate post-injection monitoring period for hypersensitivity or anaphylaxis, and the visit is documented including injection site, dose, lot number, and any immediate adverse reactions. Billing captures the HCPCS Level II code Q5154, appropriate modifiers as indicated, and the primary ICD-10 diagnosis code that justifies use of omalizumab therapy. Typical sites of service include outpatient infusion centers, allergy/immunology clinics, and ambulatory care clinics. Common payors for authorization and reimbursement processes include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|